Vertex Pharmaceuticals
Search results
13 Jun 2024 · Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine. mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older.
26 Jun 2024 · Moderna Inc respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday. In their clinical trials, GSK’s RSV vaccine ...
28 Jun 2024 · Pharmaceutical laboratories are researching new applications for mRNA vaccine technology — and Moderna is hoping to integrate COVID-19, influenza and respiratory syncytial virus immunization ...
10 Jun 2024 · mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older.
10 Jun 2024 · Vaccine maker Moderna announced positive late-stage trial results for its Covid-flu combination vaccine. There could be a combined Covid-19 and flu shot in our future, although it won’t be ready...
10 Jun 2024 · Drug company Moderna says its combined flu and Covid vaccine, which targets the two diseases in a single shot, has passed a vital part of final-stage scientific checks.
10 Jun 2024 · Moderna is the first company to release positive phase three data on a Covid and flu combination shot, giving it a lead over rivals Pfizer and Novavax.
